Skip to content
Subscriber Only

Novartis’s Gilenya Fails to Help Hard-to-Treat Form of MS

Novartis AG’s multiple sclerosis drug Gilenya failed to help patients with one of the most difficult-to-treat forms of the disease.

In an advanced study involving 970 people with primary-progressive MS, there was no significant difference between those who were treated with Gilenya and those who got a placebo, Basel, Switzerland-based Novartis said in a statement today.